World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
34025
World Ranking
9297
National Ranking
4797

Ashish M. Kamat publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ashish M. Kamat sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 818 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ashish M. Kamat D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ashish M. Kamat sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 97 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ashish M. Kamat is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medical and surgical aspects of oncology, with a significant emphasis on urology and bladder cancer treatments.

The scientist's publication record spans 830 works within the field of Medicine, distributed across several specialized subfields including Surgery (536 publications), Oncology (88), Pulmonary and Respiratory Medicine (61), Molecular Biology (60), and Urology (60). The main topics addressed in their work include:

  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Urological Disorders and Treatments
  • Epigenetics and DNA Methylation
  • Cancer Immunotherapy and Biomarkers
  • Esophageal Cancer Research and Treatment
  • Renal cell carcinoma treatment

Recent notable papers authored or co-authored by Ashish M. Kamat include:

  • "Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study" (2021, The Lancet Oncology)
  • "Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial" (2020, The Lancet Oncology)
  • "Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors" (2023, European Urology)
  • "Current best practice for bladder cancer: a narrative review of diagnostics and treatments" (2022, The Lancet)
  • "Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma" (2020, Nature Medicine)

The venues most frequently publishing their work include:

  • The Journal of Urology (69 publications)
  • Journal of Clinical Oncology (52)
  • Urologic Oncology Seminars and Original Investigations (35)
  • European Urology (32)
  • European Urology Oncology (32)

Frequent collaborators in their research projects are:

  • Colin P. Dinney
  • Roger Li
  • Neema Navai
  • Kelly K. Bree
  • Patrick J. Hensley

Best Publications

  • Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration

    Vitaly Margulis;Shahrokh F. Shariat;Surena F. Matin;Ashish M. Kamat

  • Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

    Sam S. Chang;Bernard H. Bochner;Roger Chou;Robert Dreicer

  • Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018

    Marcus George Kwesi Cumberbatch;Ibrahim Jubber;Peter C. Black;Francesco Esperto

  • CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

    Chrysoula I. Liakou;Ashish Kamat;Derek Ng Tang;Hong Chen

  • Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

    Bradley C. Carthon;Jedd D. Wolchok;Jianda Yuan;Ashish Kamat

  • Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

    David J. McConkey;Woonyoung Choi;Lauren Marquis;Frances Martin

  • Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

    Ashish M. Kamat;Richard J. Sylvester;Andreas Böhle;Joan Palou

  • Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.

    Arjun V Balar;Ashish M Kamat;Girish S Kulkarni;Edward M Uchio

  • Focus on bladder cancer

    Colin P.N. Dinney;David J. McConkey;Randall E. Millikan;Xifeng Wu

  • Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.

    Ashish M. Kamat;Colin P. N. Dinney;Jason R. Gee;H. Barton Grossman

  • A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer

    David J McConkey;Woonyoung Choi;Yu Shen;I. Ling Lee

  • Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

    Ashish M. Kamat;Thomas W. Flaig;H. Barton Grossman;Badrinath Konety

  • ZKSCAN3 Is a Master Transcriptional Repressor of Autophagy

    Santosh Chauhan;Jinesh G. Goodwin;Swati Chauhan;Ganiraju Manyam

  • Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review

    Marcus George Kwesi Cumberbatch;Beat Foerster;Beat Foerster;James W.F. Catto;Ashish M. Kamat

  • ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers

    Ashish M. Kamat;Paul K. Hegarty;Jason R. Gee;Peter E. Clark

  • Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

    Stephen A. Boorjian;Mehrdad Alemozaffar;Badrinath R. Konety;Neal D. Shore

  • An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer

    Girish S. Kulkarni;Oliver W. Hakenberg;Juergen E. Gschwend;George Thalmann

  • Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma.

    Surena F. Matin;Vitaly Margulis;Ashish Kamat;Christopher G. Wood

  • Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

    Hong Chen;Chrysoula I. Liakou;Ashish Kamat;Curtis Pettaway

  • Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.

    Jianjun Gao;Neema Navai;Omar Alhalabi;Arlene Siefker-Radtke

Frequent Co-Authors

Colin P. Dinney
Colin P. Dinney The University of Texas MD Anderson Cancer Center
H. Barton Grossman
H. Barton Grossman The University of Texas MD Anderson Cancer Center
Louis L. Pisters
Louis L. Pisters The University of Texas MD Anderson Cancer Center
Wassim Kassouf
Wassim Kassouf McGill University
Surena F. Matin
Surena F. Matin The University of Texas MD Anderson Cancer Center
Bogdan Czerniak
Bogdan Czerniak The University of Texas MD Anderson Cancer Center
Seth P. Lerner
Seth P. Lerner Baylor College of Medicine
Shahrokh F. Shariat
Shahrokh F. Shariat Medical University of Vienna
Xifeng Wu
Xifeng Wu Zhejiang University
Yair Lotan
Yair Lotan The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees is a smart way to expand your career opportunities in the healthcare field. Many students interested in medicine consider online nursing programs, which offer flexibility and can fast-track entry into clinical roles.

Affordable options are available for those looking to advance their qualifications, such as the cheapest dnp programs for nurses pursuing doctoral-level expertise. For registered nurses wanting to earn their Bachelor of Science in Nursing, cheap rn to bsn programs provide a practical pathway to career growth without excessive cost.

If you hold a non-nursing bachelor’s degree but wish to enter the nursing field, direct entry msn programs for non-nursing majors online offer a streamlined route to a master’s degree and new career options.

Those seeking accessible nursing programs can review whats the easiest nursing program to get into? to find schools that cater to diverse educational backgrounds. These alternatives can be an excellent starting point or complement to a medical education in the USA.

Best Scientists Citing Ashish M. Kamat

Trending Scientists

Recently Published Articles